adm03820
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Dec 4, 2020 (NCT04592549)
Timeline
Indications
Mechanism of action
- SARS-CoV-2Immunity, passive
SARS-CoV-2 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05142527 | Phase 2/Phase 3 (Phase 3) | Dec 31, 2021 | Ology Bioservices |
| NCT04592549 | Phase 1 | Dec 4, 2020 | Ology Bioservices |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ology Bioservices | For profit | 2 | 2 | 2 | 2020 |
1 organizations
Page 1 / 1